YAP1 and head and neck squamous cell carcinoma: Because previous studies had shown that the transcription co‐regulator YAP1 is upregulated following trametinib treatment [19] and that YAP1 can mediate EGFR overexpression [31], we hypothesized that trametinib treatment would induce both YAP1 and EGFR overexpression and activation in treated HNSCC cell lines.